Abstracts tagged "Collagen"

Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Sofie Falkenløve Madsen¹, Dovile Sinkeviciute², Christian Thudium², Morten Karsdal² and Anne-Christine Bay-Jensen², ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
Abstract Number: 2044 • ACR Convergence 2022
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
Elodie Riviere¹, Juliette Pascaud¹, Franck Letourneur², Gaetane Nocturne³ and Xavier Mariette⁴, ¹Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ²Genomic, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ³APHP, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France
Background/Purpose: Salivary gland epithelial cells (SGECs) are not only the target of autoimmunity in primary Sjögren's syndrome (pSS). SGECs may interact with lymphocytes and therefore…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2176 • ACR Convergence 2022
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Signe Holm Nielsen¹, Sine Søndergaard Korsholm², Axel Diederichsen³, Morten Karsdal¹, John Bonde Knudsen⁴, Anne-Christine Bay-Jensen¹, Louise Diederichsen⁵ and Christoffer Tandrup Nielsen⁶, ¹Nordic Bioscience, Herlev, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Dept of Rheumatology, Odense University Hospital (OUH), Odense, Denmark, ³Dept of Cardiology, OUH, Odense, Denmark, Odense, ⁴Dept of Rheumatology, OUH, Odense, Denmark., Odense, ⁵Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and internal organs. Cardiac involvement, pulmonary arterial hypertension (PAH), and interstitial lung…
Abstract Number: 0539 • ACR Convergence 2021
Vgll3-transgenic Autoimmune Mice Display Features of Cutaneous Fibrosis
Mehrnaz Gharaee-Kermani¹, Allison Billi², Marisa Hildebrandt², Jacob Martens³, Rachael Wasikowski², Joanne (Michelle) Kahlenberg¹ and Johann Gudjonsson², ¹Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI
Background/Purpose: Fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling and can lead to disfiguring skin changes. In cutaneous lupus, scar formation…
Abstract Number: 1128 • ACR Convergence 2021
Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Liubov Arbeeva¹, Duncan Lascelles², Jordan Renner¹, Yvonne Golightly¹, Morten Karsdal³, Anne-Christine Bay-Jensen³ and Richard Loeser⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina State University, Raleigh, NC, ³Nordic Bioscience, Herlev, Denmark, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: To determine inter-relationships between blood-based collagen formation and degradation biomarkers and multiple joint osteoarthritis (MJOA) phenotypes in a community-based cohort.Methods: Data were from Johnston…
Abstract Number: 1475 • ACR Convergence 2021
Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants
Frederik Gillesberg¹, Amalie Engstrøm¹, Morten Karsdal², Anne-Christine Bay-Jensen³ and Christian S Thudium³, ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Mechanical loading of cartilage is an essential part of the function and maintenance of the joint. Despite the apparent importance of continuous mechanical loading,…
Abstract Number: 1913 • ACR Convergence 2020
Investigation of the Cellular Mechanism for Estradiol-Induced Dermal Fibrosis
DeAnna Baker Frost¹, Alisa Savchenko², Adeyemi Ogunleye³, Milton Armstrong² and Carol Feghali-Bostwick⁴, ¹The Medical University of South Carolina, Charleston, ²Medical University of South Carolina, Charleston, SC, ³University of North Carolina Chapel Hill, Chapel Hill, NC, ⁴The Medical University of South Carolina, Charleston, SC
Background/Purpose: Estradiol (E2), one of the three forms of estrogen, is pro-fibrotic in the skin because it positively influences ECM production in the dermis. In…
Abstract Number: 0355 • ACR Convergence 2020
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Georg Schett¹, Matthew J. Loza², Arumugam Palanichamy², Oliver FitzGerald³, Christopher Ritchlin⁴, Frédéric Baribaud⁵ and Kristen Sweet⁵, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Janssen Research & Development, LLC, Spring House, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active…
Abstract Number: 0424 • ACR Convergence 2020
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Kristina Wells¹, Marcela Ferrada², Emily Rose², Keith Sikora³, Wendy Goodspeed², Kaitlin Quinn⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ²Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are…
Abstract Number: 1106 • ACR Convergence 2020
MMP Mediated Type I Collagen Degradation Is Associated with Erosive Hand Osteoarthritis in a Hospital-based Observational Cohort – the NOR-HAND Study
Christian Thudium¹, Neha Sharma², Marthe Gløersen³, Peder Frederiksen², Anne C. Bay-Jensen¹ and Ida Haugen³, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, ³Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Hand osteoarthritis (OA) is a common degenerative joint disease affecting mainly the interphalangeal and first carpometacarpal joints. The disease manifests as inflammation and deterioration…
Abstract Number: 1108 • ACR Convergence 2020
Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening
Yves Henrotin¹, Anne-Christine Hick², Berenice Costes³, Alain Labasse³, Thierry Conrozier⁴, Michel Malaise⁵, Yves Maugars⁶, Franz Pelousse⁷, Jean-Marc Lemaire⁸, Cedric Tits⁹, Thibault Helleputte⁹ and Damien Loeuille¹⁰, ¹University of Liège, Liège, Belgium, ²Artialis SA, Liège, Belgium, ³Artialis SA, Liege, Belgium, ⁴5. Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France, ⁵University of Liège, Liege, Belgium, ⁶Service de rhumatologie, Hôtel-Dieu, CHU de Nantes, Nantes, France, ⁷SODIRAY, Solution Diagnostique Radiologique, Liège, Belgium, ⁸SODIRAY, Solution Diagnostique Radiologique, Liege, Belgium, ⁹Data-Driven Precision Medicine, DNAlytics, Louvain-la-Neuve, Belgium, ¹⁰CHU NANCY Rheumatology, NANCY
Background/Purpose: To identify if biochemical markers s-Coll2-1, a peptide of type collagen and its nitrated from, s-Coll2-1NO2 are associated to knee osteoarthritis (OA), focusing on…
Abstract Number: 1256 • ACR Convergence 2020
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Shinjiro Kaieda¹, Kyoko Fujimoto¹ and Hiroaki Ida¹, ¹Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis in…
Abstract Number: 1040 • 2019 ACR/ARP Annual Meeting
Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity
Walcy Teodoro¹, Ana Paula Velosa ², Zelita Aparecida Queiroz ¹, Lais Araujo ³, Sergio Catanozi ¹, Antonio dos Santos Filho ⁴, Cleonice Bueno ⁴, Margarete Vendramini ⁴, Sandra Moraes Fernezlian ¹, Esmeralda Eher ⁴, Jurandir Tomaz de Miranda ¹, Fernanda Lopes ⁴, Sandra G. Pasoto ⁵, Percival Degrava Sampaio-Barros ⁶ and Vera Luiza Capelozzi ¹, ¹Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil
Background/Purpose: A better knowledge of the mechanisms and biomarkers of skin and lung damage in systemic sclerosis (SSc) related fibrosis remain a challenge. Our aim was…
Abstract Number: 44 • 2018 ACR/ARHP Annual Meeting
Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis
Lisa Goschl¹, Victoria Saferding², Johan Bäcklund³, Clemens Scheinecker⁴, Josef S. Smolen⁵, Günter Steiner⁶, Wilfried Ellmeier¹ and Michael Bonelli⁷, ¹Medical University of Vienna,Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria, ²Medical University of Vienna, Austria, Vienna, Austria, ³Karolinska Institute,Department of Medical Biochemistry and Biophysics, Stockholm, Sweden, ⁴Medical University of Vienna, Divison of Rheumatology, Vienna, Austria, ⁵Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ⁷Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].